How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study

Table 1 Demographic and clinical features of the two groups before and after infliximab approval

	Group A (n = 48)	Group B (n = 62)	P value
Age at diagnosis, yr	14.4 (12.2-17.1)	15.8 (13.1-16.5)	0.574c
Total duration of follow up with treatment, yr	4.0 (4.0-5.0)	5.5 (3.0-6.9)	0.073c
PUCAIa at diagnosis	35 (30-65)	45 (35-55)	0.969c
Hemoglobin at diagnosis, g/dL	12.3 (10.5-14.1)	12.1 (9.6-13.5)	0.245c
Albumin at diagnosis, g/dL	4.3 (4.0-4.6)	4.2 (3.9-4.6)	0.702c
ESR at diagnosis, mm/h	14.5 (7-31.3)	20 (7.5-39)	0.249c
CRP at diagnosis, mg/dL	0.04 (0.03-0.13)	0.12 (0.03-0.56)	0.791c
Disease extent of Paris classification at diagnosis			0.018d
E1 proctitis	18 (37.5)	13 (21)
E2 left colitis	8 (16.7)	8 (12.9)
E3 right colitis	6 (12.5)	7 (11.3)
E4 pancolitis	16 (33.3)	34 (54.8)
Mayo endoscopic subscore at diagnosisb			0.310d
0 normal or inactive	0	0
1 mild	12 (25.0)	7 (11.3)
2 moderate	26 (54.2)	43 (69.4)
3 severe	10 (20.8)	12 (19.4)
Corticosteroid use at baseline	21 (43.8)	30 (48.4)	0.630d
Corticosteroid-dependent	8/21 (38.1)	9/30 (30.0)	0.550d
Corticosteroid-refractory	1/21 (4.8)	1/30 (3.3)	0.360d
Cumulative number receiving medication by			0.211d
3 mo after diagnosis			0.453d
5-aminosalicylate	48 (100)	60 (96.8)
Azathioprine	42 (87.5)	51 (82.3)
Methotrexate	0 (0)	1 (1.6)
Cyclosporine	1 (2.1)	0 (0)

^aPediatric Ulcerative Colitis Activity Index (PUCAI) is a 6-item disease activity index intended for use in pediatric UC clinical trials with a score ranging from 0-85.

^bMayo endoscopy subscores were as follows: 0: Normal or inactive disease; 1: Mild disease; 2: Moderate disease; and 3: Severe disease.

^cχ² test.

^dMann-Whitney test.

Values are n (percentage) or median (interquartile range); n: Number of patients; PUCAI: Pediatric Ulcerative Colitis Activity Index.